Argenica Therapeutics’ (ASX:AGN) study delivers “encouraging” results for ARG-007 in treating traumatic brain injury

• Argenica Therapeutics (AGN) delivers “encouraging” results from a preclinical study assessing the efficiency of ARG-007 in treating modTBI
• The study employed an impact-acceleration rat model to measure the accumulation of ‘key’ proteins that contributed to modTBI in rats
• The study highlighted ARG-007 to significantly reduce damage and inflammation to brain cells caused by modTBI compared to its placebo-treated models
• The data from the study is set to form a comprehensive preclinical package to progress into human clinical trials for TBI
• AGN closed 6.94 per cent higher, trading at 38.5 cents at market close

Argenica Therapeutics (AGN) has delivered “encouraging” results from a preclinical study assessing the efficiency of ARG-007 in treating moderate traumatic brain injury (modTBI).

The study employed an impact-acceleration rat model to measure the accumulation of ‘key’ proteins that contributed to modTBI in rats, mimicking injuries sustained during a fall or motor vehicle accident.

AGN reported that results from the study highlighted ARG-007 to significantly reduce damage and inflammation to brain cells caused by modTBI compared to its placebo-treated models.

ARG-007-treated rats also showed significant improvement in functional outcomes, including increased weight gain and reduced anxiety, as well as a more sustained improvement in balance.

The study was carried out with Professor Lindy Fitzgerald at Curtin University and the Perron Institute for Neurological and Translational Sciences.

AGN Managing Director Dr Liz Dallimore said the company was “extremely pleased” with the results from its preclinical study.

“The study indicates that injury caused by moderate traumatic brain injury may be limited by the introduction of ARG-007 shortly thereafter, so we are extremely encouraged by this data,” she said.

“We now look forward to undertaking further studies, supported by funds provided by our CRC-P grant, to provide greater evidence of ARG-007’s efficacy in TBI before establishing a clinical program of work.”

Argenica announced it would continue working with its partners at Curtin University, the University of Adelaide, AusPep, and Connectivity TBI Australia, to undertake further studies of ARG-007 in modTBI in ferrets.

The data is set to form a comprehensive preclinical package to progress into human clinical trials for TBI.

AGN shares closed 6.94 per cent higher, trading at 38.5 cents at market close.